Tuesday 11 June 2013

Blocking Biosimilars


undefined

Blocking Biosimilars 
As the U.S. Food and Drug Administration (FDA) continues to finalize regulations to establish a pathway for approving biopharmaceutical or biosimilar drugs, leading branded drug manufacturers are looking ahead and lobbying state legislatures to enact laws that would limit the substitution of biogenerics for brand-name drugs. Currently, pharmacists in most states can substitute lower-cost generics for branded chemical or small-molecule drugs without such approval.



BY WORLD DRUG TRACKER

No comments:

Post a Comment